Ken Griffin Summit Therapeutics Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 23,400 shares of SMMT stock, worth $182,520. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,400
Previous 15,800
48.1%
Holding current value
$182,520
Previous $41,000
134.15%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding SMMT
# of Institutions
107Shares Held
41.3MCall Options Held
103KPut Options Held
29.9K-
Black Rock Inc. New York, NY9.82MShares$76.6 Million0.0% of portfolio
-
State Street Corp Boston, MA8.11MShares$63.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.27MShares$56.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.15MShares$24.6 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.07MShares$8.37 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $1.57B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...